Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2012

Open Access 01-12-2012 | Research article

Characterization of human gastric carcinoma-related methylation of 9 miR CpG islands and repression of their expressions in vitro and in vivo

Authors: Yantao Du, Zhaojun Liu, Liankun Gu, Jing Zhou, Bu-dong Zhu, Jiafu Ji, Dajun Deng

Published in: BMC Cancer | Issue 1/2012

Login to get access

Abstract

Background

Many miR genes are located within or around CpG islands. It is unclear whether methylation of these CpG islands represses miR transcription regularly. The aims of this study are to characterize gastric carcinoma (GC)-related methylation of miR CpG islands and its relationship with miRNA expression.

Methods

Methylation status of 9 representative miR CpG islands in a panel of cell lines and human gastric samples (including 13 normal biopsies, 38 gastritis biopsies, 112 pairs of GCs and their surgical margin samples) was analyzed by bisulfite-DHPLC and sequencing. Mature miRNA levels were determined with quantitative RT-PCR. Relationships between miR methylation, transcription, GC development, and clinicopathological characteristics were statistically analyzed.

Results

Methylation frequency of 5 miR CpG islands (miR-9-1, miR-9-3, miR-137, miR-34b, and miR-210) gradually increased while the proportion of methylated miR-200b gradually decreased during gastric carcinogenesis (Ps < 0.01). More miR-9-1 methylation was detected in 62%-64% of the GC samples and 4% of the normal or gastritis samples (18/28 versus 2/48; Odds ratio, 41.4; P < 0.01). miR-210 methylation showed high correlation with H. pylori infection. miR-375, miR-203, and miR-193b methylation might be host adaptation to the development of GCs. Methylation of these miR CpG islands was consistently shown to significantly decrease the corresponding miRNA levels presented in human cell lines. The inverse relationship was also observed for miR-9-1, miR-9-3, miR-137, and miR-200b in gastric samples. Among 112 GC patients, miR-9-1 methylation was an independent favourable predictor of overall survival of GC patients in both univariate and multivariate analysis (P < 0.02).

Conclusions

In conclusion, alteration of methylation status of 6 of 9 tested miR CpG islands was characterized in gastric carcinogenesis. miR-210 methylation correlated with H. pylori infection. miR-9-1 methylation may be a GC-specific event. Methylation of miR CpG islands may significantly down-regulate their transcription regularly.
Appendix
Available only for authorised users
Literature
1.
Hu X, Macdonald DM, Huettner PC, Feng Z, El Naqa IM, Schwarz JK, Mutch DG, Grigsby PW, Powell SN, Wang X: A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol. 2009, 114 (3): 457-464. 10.1016/j.ygyno.2009.05.022.CrossRefPubMed
2.
Lu Y, Ryan SL, Elliott DJ, Bignell GR, Futreal PA, Ellison DW, Bailey S, Clifford SC: Amplification and overexpression of Hsa-miR-30b, Hsa-miR-30d and KHDRBS3 at 8q24.22-q24.23 in medulloblastoma. PLoS One. 2009, 4 (7): e6159-10.1371/journal.pone.0006159.CrossRefPubMedPubMedCentral
3.
Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, Bednarikova M, Nenutil R, Vyzula R: Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology. 2007, 72 (5–6): 397-402.PubMed
4.
Markou A, Tsaroucha EG, Kaklamanis L, Fotinou M, Georgoulias V, Lianidou ES: Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem. 2008, 54 (10): 1696-1704. 10.1373/clinchem.2007.101741.CrossRefPubMed
5.
Corthals SL, Jongen-Lavrencic M, de Knegt Y, Peeters JK, Beverloo HB, Lokhorst HM, Sonneveld P: Micro-RNA-15a and micro-RNA-16 expression and chromosome 13 deletions in multiple myeloma. Leuk Res. 2010, 34 (5): 677-681. 10.1016/j.leukres.2009.10.026.CrossRefPubMed
6.
Dijkstra MK, van Lom K, Tielemans D, Elstrodt F, Langerak AW, van ’t Veer MB, Jongen-Lavrencic M: 17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation. Leukemia. 2009, 23 (3): 625-627. 10.1038/leu.2008.264.CrossRefPubMed
7.
Murchison EP, Partridge JF, Tam OH, Cheloufi S, Hannon GJ: Characterization of Dicer-deficient murine embryonic stem cells. Proc Natl Acad Sci U S A. 2005, 102 (34): 12135-12140. 10.1073/pnas.0505479102.CrossRefPubMedPubMedCentral
8.
Tie J, Pan Y, Zhao L, Wu K, Liu J, Sun S, Guo X, Wang B, Gang Y, Zhang Y, et al: MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genet. 2010, 6 (3): e1000879-10.1371/journal.pgen.1000879.CrossRefPubMedPubMedCentral
9.
Laneve P, Gioia U, Andriotto A, Moretti F, Bozzoni I, Caffarelli E: A minicircuitry involving REST and CREB controls miR-9-2 expression during human neuronal differentiation. Nucleic Acids Res. 2010, 38 (20): 6895-6905. 10.1093/nar/gkq604.CrossRefPubMedPubMedCentral
10.
Lu L, Katsaros D, de la Longrais IA, Sochirca O, Yu H: Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. Cancer Res. 2007, 67 (21): 10117-10122. 10.1158/0008-5472.CAN-07-2544.CrossRefPubMed
11.
Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Körner H, Knyazev P, Diebold J, Hermeking H: Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle. 2008, 7 (16): 2591-2600. 10.4161/cc.7.16.6533.CrossRefPubMed
12.
Furuta M, Kozaki KI, Tanaka S, Arii S, Imoto I, Inazawa J: miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis. 2010, 31 (5): 766-776. 10.1093/carcin/bgp250.CrossRefPubMed
13.
Tsuruta T, Kozaki K, Uesugi A, Furuta M, Hirasawa A, Imoto I, Susumu N, Aoki D, Inazawa J: miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer. Cancer Res. 2011, 71 (20): 6450-6462. 10.1158/0008-5472.CAN-11-0364.CrossRefPubMed
14.
Tsai KW, Wu CW, Hu LY, Li SC, Liao YL, Lai CH, Kao HW, Fang WL, Huang KH, Chan WC, et al: Epigenetic regulation of miR-34b and miR-129 expression in gastric cancer. Int J Cancer. 2011, 129 (11): 2600-2610. 10.1002/ijc.25919.CrossRefPubMed
15.
Hildebrandt MA, Gu J, Lin J, Ye Y, Tan W, Tamboli P, Wood CG, Wu X: Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma. Oncogene. 2010, 29 (42): 5724-5728. 10.1038/onc.2010.305.CrossRefPubMed
16.
Hashimoto Y, Akiyama Y, Otsubo T, Shimada S, Yuasa Y: Involvement of epigenetically silenced microRNA-181c in gastric carcinogenesis. Carcinogenesis. 2010, 31 (5): 777-784. 10.1093/carcin/bgq013.CrossRefPubMed
17.
Yang C, Cai J, Wang Q, Tang H, Cao J, Wu L, Wang Z: Epigenetic silencing of miR-130b in ovarian cancer promotes the development of multidrug resistance by targeting colony-stimulating factor 1. Gynecol Oncol. 2012, 124 (2): 325-334. 10.1016/j.ygyno.2011.10.013.CrossRefPubMed
18.
Deng D, Liu Z, Du Y: Epigenetic alterations as cancer diagnostic, prognostic, and predictive biomarkers. Adv Genet. 2010, 71: 125-176.CrossRefPubMed
19.
Lehmann U, Hasemeier B, Christgen M, Müller M, Römermann D, Länger F, Kreipe H: Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. J Pathol. 2008, 214 (1): 17-24. 10.1002/path.2251.CrossRefPubMed
20.
Bandres E, Agirre X, Bitarte N, Ramirez N, Zarate R, Roman-Gomez J, Prosper F, Garcia-Foncillas J: Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer. 2009, 125 (11): 2737-2743. 10.1002/ijc.24638.CrossRefPubMed
21.
Chen X, Hu H, Guan X, Xiong G, Wang Y, Wang K, Li J, Xu X, Yang K, Bai Y: CpG island methylation status of miRNAs in esophageal squamous cell carcinoma. Int J Cancer. 2012, 130 (7): 17-24.
22.
Kozaki K, Imoto I, Mogi S, Omura K, Inazawa J: Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res. 2008, 68 (7): 2094-2105. 10.1158/0008-5472.CAN-07-5194.CrossRefPubMed
23.
Balaguer F, Link A, Lozano JJ, Cuatrecasas M, Nagasaka T, Boland CR, Goel A: Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis. Cancer Res. 2010, 70 (16): 6609-6618. 10.1158/0008-5472.CAN-10-0622.CrossRefPubMedPubMedCentral
24.
Chen Q, Chen X, Zhang M, Fan Q, Luo S, Cao X: miR-137 is frequently down-regulated in gastric cancer and is a negative regulator of Cdc42. Dig Dis Sci. 2011, 56 (7): 2009-2016. 10.1007/s10620-010-1536-3.CrossRefPubMed
25.
Li X, Lin R, Li J: Epigenetic silencing of microRNA-375 regulates PDK1 expression in esophageal cancer. Dig Dis Sci. 2011, 56 (10): 2849-2856. 10.1007/s10620-011-1711-1.CrossRefPubMed
26.
Suzuki H, Yamamoto E, Nojima M, Kai M, Yamano HO, Yoshikawa K, Kimura T, Kudo T, Harada E, Sugai T, et al: Methylation-associated silencing of microRNA-34b/c in gastric cancer and its involvement in an epigenetic field defect. Carcinogenesis. 2010, 31 (12): 2066-2073. 10.1093/carcin/bgq203.CrossRefPubMed
27.
Tanaka N, Toyooka S, Soh J, Kubo T, Yamamoto H, Maki Y, Muraoka T, Shien K, Furukawa M, Ueno T, et al: Frequent methylation and oncogenic role of microRNA-34b/c in small-cell lung cancer. Lung Cancer. 2012, 76 (1): 32-38. 10.1016/j.lungcan.2011.10.002.CrossRefPubMed
28.
Liu Z, Shen J, Zhang L, Shen L, Li Q, Zhang B, Zhou J, Gu L, Feng G, Ma J, et al: Prevalence of A2143G mutation of H. pylori-23S rRNA in Chinese subjects with and without clarithromycin use history. BMC Microbiol. 2008, 8: 81-10.1186/1471-2180-8-81.CrossRefPubMedPubMedCentral
29.
Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, Wilson AC, Folsom AR, Wu K, Benderly M, et al: Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005, 294 (14): 1799-1809.PubMed
30.
Eads CA, Laird PW: Combined bisulfite restriction analysis (COBRA). Methods Mol Biol. 2002, 200: 71-85.PubMed
31.
Deng DJ, Deng GR, Smith MF, Zhou J, Xin HJ, Powell SM, Lu YY: Simultaneous detection of CpG methylation and single nucleotide polymorphism by denaturing high performance liquid chromatography. Nucleic Acids Res. 2002, 30 (3): 13E-10.1093/nar/30.3.e13.CrossRef
32.
Bahrami AR, Dickman MJ, Matin MM, Ashby JR, Brown PE, Conroy MJ, Fowler GJ, Rose JP, Sheikh QI, Yeung AT, et al: Use of fluorescent DNA-intercalating dyes in the analysis of DNA via ion-pair reversed-phase denaturing high-performance liquid chromatography. Anal Biochem. 2002, 309 (2): 248-252. 10.1016/S0003-2697(02)00306-8.CrossRefPubMed
33.
Luo D, Zhang B, Lv L, Xiang S, Liu Y, Ji J, Deng D: Methylation of CpG islands of p16 associated with progression of primary gastric carcinomas. Lab Invest. 2006, 86 (6): 591-598.PubMed
34.
Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature. 2005, 435 (7043): 834-838. 10.1038/nature03702.CrossRefPubMed
35.
Zheng Z, Li L, Liu X, Wang D, Tu B, Wang L, Wang H, Zhu WG: 5-Aza-2'-deoxycytidine reactivates gene expression via degradation of pRb pocket proteins. FASEB J. 2011, 26 (1): 449-459.CrossRefPubMed
36.
Tellez CS, Juri DE, Do K, Bernauer AM, Thomas CL, Damiani LA, Tessema M, Leng S, Belinsky SA: EMT and stem cell-like properties associated with miR-205 and miR-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells. Cancer Res. 2011, 71 (8): 3087-3097. 10.1158/0008-5472.CAN-10-3035.CrossRefPubMedPubMedCentral
37.
Rauhala HE, Jalava SE, Isotalo J, Bracken H, Lehmusvaara S, Tammela TL, Oja H, Visakorpi T: miR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer. Int J Cancer. 2010, 127 (6): 1363-1372. 10.1002/ijc.25162.CrossRefPubMed
38.
Chim CS, Wong KY, Leung CY, Chung LP, Hui PK, Chan SY, Yu L: Epigenetic inactivation of the hsa-miR-203 in haematological malignancies. J Cell Mol Med. 2011, 15 (12): 2760-2767. 10.1111/j.1582-4934.2011.01274.x.CrossRefPubMedPubMedCentral
39.
Tsukamoto Y, Nakada C, Noguchi T, Tanigawa M, Nguyen LT, Uchida T, Hijiya N, Matsuura K, Fujioka T, Seto M, et al: MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta. Cancer Res. 2010, 70 (6): 2339-2349. 10.1158/0008-5472.CAN-09-2777.CrossRefPubMed
40.
Tsai KW, Liao YL, Wu CW, Hu LY, Li SC, Chan WC, Ho MR, Lai CH, Kao HW, Fang WL, et al: Aberrant hypermethylation of miR-9 genes in gastric cancer. Epigenetics. 2011, 6 (10): 1189-1197. 10.4161/epi.6.10.16535.CrossRefPubMedPubMedCentral
41.
Díaz R, Silva J, García JM, Lorenzo Y, García V, Peña C, Rodríguez R, Muñoz C, García F, Bonilla F, et al: Deregulated expression of miR-106a predicts survival in human colon cancer patients. Genes Chromosomes Cancer. 2008, 47 (9): 794-802. 10.1002/gcc.20580.CrossRefPubMed
42.
43.
Sikand K, Slane SD, Shukla GC: Intrinsic expression of host genes and intronic miRNAs in prostate carcinoma cells. Cancer Cell Int. 2009, 9: 21-10.1186/1475-2867-9-21.CrossRefPubMedPubMedCentral
44.
Wilting SM, van Boerdonk RA, Henken FE, Meijer CJ, Diosdado B, Meijer GA, le Sage C, Agami R, Snijders PJ, Steenbergen RD: Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Mol Cancer. 2010, 9: 167-CrossRefPubMedPubMedCentral
45.
Delaloy C, Liu L, Lee JA, Su H, Shen F, Yang GY, Young WL, Ivey KN, Gao FB: MicroRNA-9 coordinates proliferation and migration of human embryonic stem cell-derived neural progenitors. Cell Stem Cell. 2010, 6 (4): 323-335. 10.1016/j.stem.2010.02.015.CrossRefPubMedPubMedCentral
46.
Liu S, Kumar SM, Lu H, Liu A, Yang R, Pushparajan A, Guo W, Xu X: MicroRNA-9 up-regulates E-cadherin through inhibition of NF-κB1-Snail1 pathway in melanoma. J Pathol. 2012, 226 (1): 61-72. 10.1002/path.2964.CrossRefPubMed
47.
Deng Y, Deng H, Bi F, Liu J, Bemis LT, Norris D, Wang XJ, Zhang Q: MicroRNA-137 targets carboxyl-terminal binding protein 1 in melanoma cell lines. Int J Biol Sci. 2011, 7 (1): 133-137.CrossRefPubMedPubMedCentral
48.
Langevin SM, Stone RA, Bunker CH, Grandis JR, Sobol RW, Taioli E: MicroRNA-137 promoter methylation in oral rinses from patients with squamous cell carcinoma of the head and neck is associated with gender and body mass index. Carcinogenesis. 2010, 31 (5): 864-870. 10.1093/carcin/bgq051.CrossRefPubMedPubMedCentral
49.
Langevin SM, Stone RA, Bunker CH, Lyons-Weiler MA, Laframboise WA, Kelly L, Seethala RR, Grandis JR, Sobol RW, Taioli E: MicroRNA-137 promoter methylation is associated with poorer overall survival in patients with squamous cell carcinoma of the head and neck. Cancer. 2011, 117 (7): 1454-1462. 10.1002/cncr.25689.CrossRefPubMed
50.
Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY: MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res. 2007, 67 (18): 8433-8438. 10.1158/0008-5472.CAN-07-1585.CrossRefPubMed
51.
Cho WC: Epigenetic alteration of microRNAs in feces of colorectal cancer and its clinical significance. Expert Rev Mol Diagn. 2011, 11 (7): 691-694. 10.1586/erm.11.57.CrossRefPubMed
52.
Kubo T, Toyooka S, Tsukuda K, Sakaguchi M, Fukazawa T, Soh J, Asano H, Ueno T, Muraoka T, Yamamoto H, et al: Epigenetic silencing of microRNA-34b/c plays an important role in the pathogenesis of malignant pleural mesothelioma. Clin Cancer Res. 2011, 17 (15): 4965-4974. 10.1158/1078-0432.CCR-10-3040.CrossRefPubMed
53.
Watanabe K, Emoto N, Hamano E, Sunohara M, Kawakami M, Kage H, Kitano K, Nakajima J, Goto A, Fukayama M, et al: Genome structure-based screening identified epigenetically silenced microRNA associated with invasiveness in non-small-cell lung cancer. Int J Cancer. 2012, 130 (11): 2580-2590. 10.1002/ijc.26254.CrossRefPubMed
54.
Mazar J, Khaitan D, DeBlasio D, Zhong C, Govindarajan SS, Kopanathi S, Zhang S, Ray A, Perera RJ: Epigenetic regulation of microRNA genes and the role of miR-34b in cell invasion and motility in human melanoma. PLoS One. 2011, 6 (9): e24922-10.1371/journal.pone.0024922.CrossRefPubMedPubMedCentral
55.
Suzuki H, Yamamoto E, Nojima M, Kai M, Yamano HO, Yoshikawa K, Kimura T, Kudo T, Harada E, Sugai T, et al: Methylation-associated silencing of microRNA-34b/c in gastric cancer and its involvement in an epigenetic field defect. Carcinogenesis. 2010, 31 (12): 2066-2073. 10.1093/carcin/bgq203.CrossRefPubMed
56.
Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A, Calin G, Wang H, Siefker-Radtke A, McConkey D, et al: miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res. 2009, 15 (16): 5060-5072. 10.1158/1078-0432.CCR-08-2245.CrossRefPubMed
57.
Bracken CP, Gregory PA, Kolesnikoff N, Bert AG, Wang J, Shannon MF, Goodall GJ: A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res. 2008, 68 (19): 7846-7854. 10.1158/0008-5472.CAN-08-1942.CrossRefPubMed
58.
Davalos V, Moutinho C, Villanueva A, Boque R, Silva P, Carneiro F, Esteller M: Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. Oncogene. 2012, 31 (16): 2062-2074. 10.1038/onc.2011.383.CrossRefPubMed
59.
Li A, Omura N, Hong SM, Vincent A, Walter K, Griffith M, Borges M, Goggins M: Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res. 2010, 70 (13): 5226-5237. 10.1158/0008-5472.CAN-09-4227.CrossRefPubMedPubMedCentral
60.
Ying Q, Liang L, Guo W, Zha R, Tian Q, Huang S, Yao J, Ding J, Bao M, Ge C, et al: Hypoxia-inducible microRNA-210 augments the metastatic potential of tumor cells by targeting vacuole membrane protein 1 in hepatocellular carcinoma. Hepatology. 2011, 54 (6): 2064-2075. 10.1002/hep.24614.CrossRefPubMed
61.
Tsuchiya S, Fujiwara T, Sato F, Shimada Y, Tanaka E, Sakai Y, Shimizu K, Tsujimoto G: MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1). J Biol Chem. 2011, 286 (1): 420-428. 10.1074/jbc.M110.170852.CrossRefPubMed
62.
Lages E, Guttin A, El Atifi M, Ramus C, Ipas H, Dupré I, Rolland D, Salon C, Godfraind C, de Fraipont F, et al: MicroRNA and target protein patterns reveal physiopathological features of glioma subtypes. PLoS One. 2011, 6 (5): e20600-10.1371/journal.pone.0020600.CrossRefPubMedPubMedCentral
63.
de Souza Rocha Simonini P, Breiling A, Gupta N, Malekpour M, Youns M, Omranipour R, Malekpour F, Volinia S, Croce CM, Najmabadi H, et al: Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor alpha in breast cancer cells. Cancer Res. 2010, 70 (22): 9175-9184. 10.1158/0008-5472.CAN-10-1318.CrossRefPubMed
64.
Mazar J, DeBlasio D, Govindarajan SS, Zhang S, Perera RJ: Epigenetic regulation of microRNA-375 and its role in melanoma development in humans. FEBS Lett. 2011, 585 (15): 2467-2476. 10.1016/j.febslet.2011.06.025.CrossRefPubMed
65.
Craig VJ, Cogliatti SB, Rehrauer H, Wündisch T, Müller A: Epigenetic silencing of microRNA-203 dysregulates ABL1 expression and drives Helicobacter-associated gastric lymphomagenesis. Cancer Res. 2011, 71 (10): 3616-3624. 10.1158/0008-5472.CAN-10-3907.CrossRefPubMed
Metadata
Title
Characterization of human gastric carcinoma-related methylation of 9 miR CpG islands and repression of their expressions in vitro and in vivo
Authors
Yantao Du
Zhaojun Liu
Liankun Gu
Jing Zhou
Bu-dong Zhu
Jiafu Ji
Dajun Deng
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2012
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-12-249

Other articles of this Issue 1/2012

BMC Cancer 1/2012 Go to the issue

Case report

Germline truncating-mutations in BRCA1 and MSH6 in a patient with early onset endometrial cancer

Research article

Genetic association with overall survival of taxane-treated lung cancer patients - a genome-wide association study in human lymphoblastoid cell lines followed by a clinical association study

Research article

Aberrant methylation of the M-type phospholipase A2 receptor gene in leukemic cells

Research article

Mechanistic studies of Gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells

Study protocol

A randomized controlled trial on the effectiveness of strength training on clinical and muscle cellular outcomes in patients with prostate cancer during androgen deprivation therapy: rationale and design

Research article

Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma coexists with increased expression of mTOR kinase in endometrioid endometrial carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits